Aclaris Therapeutics (ACRS) Upgraded to “Sell” by BidaskClub

BidaskClub upgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a strong sell rating to a sell rating in a research report sent to investors on Saturday morning.

Several other brokerages have also recently weighed in on ACRS. Zacks Investment Research cut shares of Aclaris Therapeutics from a buy rating to a hold rating in a research report on Tuesday, November 20th. JMP Securities lowered their price target on shares of Aclaris Therapeutics from $47.00 to $34.00 and set a buy rating on the stock in a research report on Tuesday, October 16th. Finally, Cantor Fitzgerald reissued a buy rating and set a $50.00 price target on shares of Aclaris Therapeutics in a research report on Tuesday, November 6th. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. Aclaris Therapeutics presently has a consensus rating of Buy and an average target price of $39.70.

Aclaris Therapeutics stock opened at $9.32 on Friday. Aclaris Therapeutics has a 52-week low of $8.23 and a 52-week high of $26.25.

Aclaris Therapeutics (NASDAQ:ACRS) last released its earnings results on Tuesday, November 6th. The biotechnology company reported ($1.06) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.25) by $0.19. The business had revenue of $1.63 million during the quarter, compared to analyst estimates of $1.58 million. Aclaris Therapeutics had a negative net margin of 1,578.24% and a negative return on equity of 63.74%. Analysts expect that Aclaris Therapeutics will post -4 earnings per share for the current fiscal year.

In related news, Director Anand Mehra bought 372,093 shares of the firm’s stock in a transaction on Monday, October 22nd. The shares were bought at an average price of $10.75 per share, with a total value of $3,999,999.75. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen A. Tullman bought 7,100 shares of the firm’s stock in a transaction on Thursday, October 4th. The stock was bought at an average cost of $14.00 per share, for a total transaction of $99,400.00. Following the transaction, the director now directly owns 177,457 shares of the company’s stock, valued at $2,484,398. The disclosure for this purchase can be found here. Insiders own 17.00% of the company’s stock.

Hedge funds and other institutional investors have recently bought and sold shares of the business. Royal Bank of Canada lifted its position in Aclaris Therapeutics by 561.0% in the first quarter. Royal Bank of Canada now owns 6,517 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 5,531 shares during the last quarter. Bank of Montreal Can acquired a new position in Aclaris Therapeutics in the second quarter valued at about $159,000. Granite Investment Partners LLC acquired a new position in Aclaris Therapeutics in the second quarter valued at about $164,000. CIBC Private Wealth Group LLC acquired a new position in Aclaris Therapeutics in the second quarter valued at about $200,000. Finally, State Board of Administration of Florida Retirement System acquired a new position in Aclaris Therapeutics in the second quarter valued at about $215,000. 99.43% of the stock is currently owned by institutional investors.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

See Also: Call Option

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit